Monissa C Paderes

Dr. Monissa C Paderes

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2023 in ChemistryOpen
Verified
Journal Article
Open access
RHRajelle D. Hernandez
Rajelle D. Hernandez
FGFrances Abygail F. Genio
Frances Abygail F. Genio
JCJannelle R. Casanova
Jannelle R. Casanova
MCMarlon T. Conato
Marlon T. Conato
Monissa C PaderesMonissa C Paderes
Monissa C Paderes
Rotenone is a naturally occurring compound shown to exhibit antiproliferative activity against various cancer cell lines, indicating its potential as a lead anticancer agent. However, its toxicity against normal cells has prompted further investigation and chemical modifications. In this study, a library of carbonyl group‐modified rotenone derivatives was synthesized and evaluated for their antiproliferative activities against MCF‐7 breast cancer cells, A549 human lung carcinoma cells, and HCT116 human colorectal cancer cells using 3‐(4, 5‐dimethylthiazolyl‐2)‐2, 5‐diphenyltetrazolium bromide (MTT) assay. The results showed several promising compounds that inhibited cell proliferation. Specifically, the oxime and alcohol rotenone derivatives exhibited antiproliferative activities against all 3 cancer cell lines, while the ethoxy, carbamate, and alkene derivatives are selective against MCF‐7 (IC50=5.72 μM), HCT116 (IC50=8.86 μM), and A549 (IC50=0.11 μM), respectively. SwissADME analysis showed that the physicochemical properties and drug‐likeness of the synthesized rotenone derivatives were within the set limits, suggesting the favorable characteristics of these compounds for drug development. The findings obtained in this work highlight the potential of rotenone derivatives as promising chemotherapeutic candidates.

11 May 2022 in Chemistry – An Asian Journal
Verified
Journal Article
Closed access
Monissa C PaderesMonissa C Paderes
Monissa C Paderes
MDMark Jeffrey Diaz
Mark Jeffrey Diaz
CPCris Angelo Pagtalunan
Cris Angelo Pagtalunan
DBDwight Angelo Bruzon
Dwight Angelo Bruzon
GTGiovanni Tapang
Giovanni Tapang

15 June 2020 in ACS Applied Polymer Materials
Verified
Journal Article
Closed access
Monissa C PaderesMonissa C Paderes
Monissa C Paderes
CJCraig James
Craig James
SJScott A. Jamieson
Scott A. Jamieson
AMAnh Hung Mai
Anh Hung Mai
JLJuan Hermoso Limon
Juan Hermoso Limon
EFEmiliano Fratini
Emiliano Fratini

17 August 2021 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
FGFrances Abygail F. Genio
Frances Abygail F. Genio
Monissa C PaderesMonissa C Paderes
Monissa C Paderes

16 August 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RRReuben James Z. Rosal
Reuben James Z. Rosal
Monissa C PaderesMonissa C Paderes
Monissa C Paderes
O-Alkylated and acylated quercetin derivatives were found to inhibit SARS-CoV-2 S:ACE2 interaction in vitro and exhibited low hepato-, nephro-, and cardiotoxicity.

2 November 2023 in ACS Omega
Verified
Journal Article
Open access
JFJohn Alfon P. Francisco
John Alfon P. Francisco
Monissa C PaderesMonissa C Paderes
Monissa C Paderes
Deguelin has been extensively studied for its anticancer properties; however, its clinical application has been hindered by concerns about in vivo toxicity. Structural modifications of deguelin including ring truncation have been explored to enhance its pharmacological properties. In this study, the design and straightforward synthesis of a series of B, C, and E (BCE)-ring-truncated deguelin analogues with deoxybenzoin backbone were described. The structure-activity relationships (SARs) were established by evaluation of their inhibitory activities against three cancer cell lines, A549 (adenocarcinomic human alveolar basal epithelial cells), HCT116 (human colorectal cancer cells), and MCF-7 (breast cancer cells). Six derivatives demonstrated significant and selective inhibitory activities. The ketone derivative 3a showed potency against A549 (IC50 = 6.62 μM) while the oxime analogue 6a and D-ring-benzylated ketone analogue 8d exhibited activity against HCT116 (IC50 = 3.43 and 6.96 μM, respectively). Moreover, the D-ring alkylated derivatives 8c and 8e-f were active against MCF-7 cells (IC50 < 10 μM). The potential suitability of the BCE-ring-truncated deguelin derivatives for drug development was further supported by the favorable in silico prediction of their physicochemical properties, druglikeness, and toxicity. This study could provide valuable insights for the further development of novel anticancer agents.